Dermatology Clinical Trials

Pruritus, also known as itching, is a common symptom of eczema. Itching is often one of the first symptoms that people with eczema experience and can be one of the most distressing aspects of the condition. Pruritus affects 90% of adults who have Eczema. Some conventional treatments include moisturizers, topical corticosteroids, topical or oral immunomodulators, and allergen avoidance. Pruritis (itching) associated with eczema can be debilitating We are conducting clinical trials to assess the efficacy and safety of potential new treatments that can improve Atopic dermatitis.

Vitiligo causes white patches or depigmentation of the skin; it is the most common form of vitiligo. It affects around 0.5% – 2% of the population globally. Vitiligo can occur at any age and affects people of all races and ethnicities. Currently limited treatment options include topical steroids, vitamin D3, calcineurin inhibitors, topical immunomodulators, phototherapy, surgical treatments, and camouflage. MetroBoston is conducting clinical trials in vitiligo to determine the safety and efficacy of new potential treatments that may improve skin pigmentation.

Alopecia areata is a condition occurring as a result of an autoimmune disorder. The condition is characterized by the sudden onset of round or oval patches of hair loss, often leaving a smooth, hairless scalp or bald patches on the body. The prevalence of alopecia areata is estimated to be around 2% of the global population. The condition often first appears during childhood or adolescence but can occur at any age. Treatment options for alopecia are limited. Alopecia can cause depression and lowered self-esteem. MetroBoston is conducting clinical trials to evaluate the safety and efficacy of new potential treatments for alopecia, which may improve this condition.